Dr Johan Vande Voorde

  • Senior Research Fellow (Therapeutic Science Research)

telephone: 01413304211
email: Johan.VandeVoorde@glasgow.ac.uk

Room 332, Wolfson Wohl Cancer Research Centre,, Garscube Estate, Switchback Road, G61 1QH

Import to contacts

ORCID iDhttps://orcid.org/0000-0002-7686-0926

Biography

ORCID

https://orcid.org/0000-0002-7686-0926

Dr Johan Vande Voorde obtained his PhD in the laboratory of Jan Balzarini (KU Leuven, Belgium) where he studied the impact of tumour-associated bacteria on chemotherapy. In 2015, he joined Eyal Gottlieb’s group at the CRUK Scotland Institute (formerly CRUK Beatson Institute). There, he studied metabolic vulnerabilities of colorectal cancer and the metabolic effects of Plasmax, a cell culture medium that more closely mimics physiology. In 2018, he joined the team of Owen Sansom, director of the CRUK Scotland Institute, as part of Cancer Grand Challenges Team Rosetta. Within this multidisciplinary consortium, he applied metabolic profiling of colorectal cancer for tissue stratification and target discovery.

Johan set up his independent research group at the University of Glasgow in 2024, funded by a CRUK Career Development Fellowship and a Lord Kelvin/Adam Smith Leadership Fellowship. His laboratory studies cancer metabolism and the role of the gut microbiome in cancer.

Research interests

The Vande Voorde lab studies metabolic rewiring in cancer. We have a particular interest in how the gut microbiome shapes metabolite availability, and the effects of microbiota on cancer progression and therapy response. In addition, we study the systemic consequences of cancer-related metabolic perturbations (e.g. muscle wasting).

GRANTS AND AWARDS

  • Cancer Research UK Career Development Fellowship (2024-2030)
  • Lord Kelvin / Adam Smith Leadership Fellowship (2024-2030)
  • Senior Research Fellowship (University of Glasgow, 2024-2028)
  • Pancreatic Cancer UK Research Innovation Fund (2022-2023)

Publications

List by: Type | Date

Jump to: 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019
Number of items: 12.

2025

Whyte, D. et al. (2025) Uridine phosphorylase-1 supports metastasis by altering immune and extracellular matrix landscapes. EMBO Reports, 26(17), pp. 4248-4282. (doi: 10.1038/s44319-025-00520-7) (PMID:40702342) (PMCID:PMC12420820)

Najumudeen, Arafath K. and Vande Voorde, Johan ORCID logoORCID: https://orcid.org/0000-0002-7686-0926 (2025) Spatial metabolomics to unravel cellular metabolism. Nature Reviews Genetics, 26(4), 228. (doi: 10.1038/s41576-025-00817-2) (PMID:39875644)

Goodwin, Richard J A, Marshall, John F, Poulogiannis, George, Yuneva, Mariia, Brindle, Kevin M, Takáts, Zoltán, Sansom, Owen J. ORCID logoORCID: https://orcid.org/0000-0001-9540-3010, Bunch, Josephine, Barry, Simon T. and Cancer Grand Challenges Rosetta Consortium, . ORCID logoORCID: https://orcid.org/0000-0002-7686-0926 (2025) Visualizing cancer heterogeneity at the molecular and cellular levels: lessons from Rosetta. Cancer Discovery, 15(1), pp. 34-38. (doi: 10.1158/2159-8290.CD-24-0016) (PMID:39801233)

2024

Jans, M. et al. (2024) Colibactin-driven colon cancer requires adhesin-mediated epithelial binding. Nature, 635(8038), pp. 472-480. (doi: 10.1038/s41586-024-08135-z) (PMID:39506107)

2023

Rattigan, K. M. et al. (2023) Arginine dependency is a therapeutically exploitable vulnerability in chronic myeloid leukaemic stem cells. EMBO Reports, 24, e56279. (doi: 10.15252/embr.202256279) (PMID:37489735) (PMCID:PMC10561355)

Vande Voorde, J. et al. (2023) Metabolic profiling stratifies colorectal cancer and reveals adenosylhomocysteinase as a therapeutic target. Nature Metabolism, 5(8), pp. 1303-1318. (doi: 10.1038/s42255-023-00857-0) (PMID:37580540) (PMCID:PMC10447251)

May, S. et al. (2023) Absent expansion of AXIN2+ hepatocytes and altered physiology in Axin2CreERT2 mice challenges the role of pericentral hepatocytes in homeostatic liver regeneration. Journal of Hepatology, 78(5), pp. 1028-1036. (doi: 10.1016/j.jhep.2023.01.009) (PMID:36702176)

Villar, V. H. et al. (2023) Hepatic glutamine synthetase controls N5-methylglutamine in homeostasis and cancer. Nature Chemical Biology, 19(3), pp. 292-300. (doi: 10.1038/s41589-022-01154-9) (PMID:36280791) (PMCID:PMC9974483)

2022

Patel, R. et al. (2022) Cyclocreatine suppresses creatine metabolism and impairs prostate cancer progression. Cancer Research, 82(14), pp. 2565-2575. (doi: 10.1158/0008-5472.CAN-21-1301) (PMID:35675421) (PMCID:PMC9381098)

2021

Najumudeen, A. K. et al. (2021) The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer. Nature Genetics, 53, pp. 16-26. (doi: 10.1038/s41588-020-00753-3) (PMID:33414552)

2020

Casciano, J. C. et al. (2020) MYC regulates fatty acid metabolism through a multigenic program in claudin-low triple negative breast cancer. British Journal of Cancer, 122(6), pp. 868-884. (doi: 10.1038/s41416-019-0711-3) (PMID:31942031) (PMCID:PMC7078291)

2019

Vande Voorde, Johan ORCID logoORCID: https://orcid.org/0000-0002-7686-0926, Ackermann, Tobias, Pfetzer, Nadja, Sumpton, David, Mackay, Gillian, Kalna, Gabriela, Nixon, Colin, Blyth, Karen ORCID logoORCID: https://orcid.org/0000-0002-9304-439X, Gottlieb, Eyal ORCID logoORCID: https://orcid.org/0000-0002-9770-0956 and Tardito, Saverio ORCID logoORCID: https://orcid.org/0000-0002-5294-8683 (2019) Improving the metabolic fidelity of cancer models with a physiological cell culture medium. Science Advances, 5(1), eaau7314. (doi: 10.1126/sciadv.aau7314) (PMID:30613774) (PMCID:PMC6314821)

This list was generated on Wed Sep 24 14:42:06 2025 BST.
Jump to: Articles
Number of items: 12.

Articles

Whyte, D. et al. (2025) Uridine phosphorylase-1 supports metastasis by altering immune and extracellular matrix landscapes. EMBO Reports, 26(17), pp. 4248-4282. (doi: 10.1038/s44319-025-00520-7) (PMID:40702342) (PMCID:PMC12420820)

Najumudeen, Arafath K. and Vande Voorde, Johan ORCID logoORCID: https://orcid.org/0000-0002-7686-0926 (2025) Spatial metabolomics to unravel cellular metabolism. Nature Reviews Genetics, 26(4), 228. (doi: 10.1038/s41576-025-00817-2) (PMID:39875644)

Goodwin, Richard J A, Marshall, John F, Poulogiannis, George, Yuneva, Mariia, Brindle, Kevin M, Takáts, Zoltán, Sansom, Owen J. ORCID logoORCID: https://orcid.org/0000-0001-9540-3010, Bunch, Josephine, Barry, Simon T. and Cancer Grand Challenges Rosetta Consortium, . ORCID logoORCID: https://orcid.org/0000-0002-7686-0926 (2025) Visualizing cancer heterogeneity at the molecular and cellular levels: lessons from Rosetta. Cancer Discovery, 15(1), pp. 34-38. (doi: 10.1158/2159-8290.CD-24-0016) (PMID:39801233)

Jans, M. et al. (2024) Colibactin-driven colon cancer requires adhesin-mediated epithelial binding. Nature, 635(8038), pp. 472-480. (doi: 10.1038/s41586-024-08135-z) (PMID:39506107)

Rattigan, K. M. et al. (2023) Arginine dependency is a therapeutically exploitable vulnerability in chronic myeloid leukaemic stem cells. EMBO Reports, 24, e56279. (doi: 10.15252/embr.202256279) (PMID:37489735) (PMCID:PMC10561355)

Vande Voorde, J. et al. (2023) Metabolic profiling stratifies colorectal cancer and reveals adenosylhomocysteinase as a therapeutic target. Nature Metabolism, 5(8), pp. 1303-1318. (doi: 10.1038/s42255-023-00857-0) (PMID:37580540) (PMCID:PMC10447251)

May, S. et al. (2023) Absent expansion of AXIN2+ hepatocytes and altered physiology in Axin2CreERT2 mice challenges the role of pericentral hepatocytes in homeostatic liver regeneration. Journal of Hepatology, 78(5), pp. 1028-1036. (doi: 10.1016/j.jhep.2023.01.009) (PMID:36702176)

Villar, V. H. et al. (2023) Hepatic glutamine synthetase controls N5-methylglutamine in homeostasis and cancer. Nature Chemical Biology, 19(3), pp. 292-300. (doi: 10.1038/s41589-022-01154-9) (PMID:36280791) (PMCID:PMC9974483)

Patel, R. et al. (2022) Cyclocreatine suppresses creatine metabolism and impairs prostate cancer progression. Cancer Research, 82(14), pp. 2565-2575. (doi: 10.1158/0008-5472.CAN-21-1301) (PMID:35675421) (PMCID:PMC9381098)

Najumudeen, A. K. et al. (2021) The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer. Nature Genetics, 53, pp. 16-26. (doi: 10.1038/s41588-020-00753-3) (PMID:33414552)

Casciano, J. C. et al. (2020) MYC regulates fatty acid metabolism through a multigenic program in claudin-low triple negative breast cancer. British Journal of Cancer, 122(6), pp. 868-884. (doi: 10.1038/s41416-019-0711-3) (PMID:31942031) (PMCID:PMC7078291)

Vande Voorde, Johan ORCID logoORCID: https://orcid.org/0000-0002-7686-0926, Ackermann, Tobias, Pfetzer, Nadja, Sumpton, David, Mackay, Gillian, Kalna, Gabriela, Nixon, Colin, Blyth, Karen ORCID logoORCID: https://orcid.org/0000-0002-9304-439X, Gottlieb, Eyal ORCID logoORCID: https://orcid.org/0000-0002-9770-0956 and Tardito, Saverio ORCID logoORCID: https://orcid.org/0000-0002-5294-8683 (2019) Improving the metabolic fidelity of cancer models with a physiological cell culture medium. Science Advances, 5(1), eaau7314. (doi: 10.1126/sciadv.aau7314) (PMID:30613774) (PMCID:PMC6314821)

This list was generated on Wed Sep 24 14:42:06 2025 BST.

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • Identifying metabolic drivers of cachexia in colorectal cancer patients
    Beatson Cancer Charity
    2025 - 2028
     
  • Leveraging microbial metabolism to improve clinical outcome in colorectal cancer
    Cancer Research UK
    2024 - 2030